Rhythm Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Rhythm Pharmaceuticals de 62.9% y 44% por año respectivamente. Se prevé que el BPA crezca en un 62.9% al año. Se espera que la rentabilidad financiera sea de -132.7% en 3 años.

Información clave

62.9%

Tasa de crecimiento de los beneficios

62.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	27.1%
Tasa de crecimiento de los ingresos	44.0%
Rentabilidad financiera futura	-132.7%
Cobertura de analistas	Good
Última actualización	04 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Recent updates

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:RYTM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	331	-54	1	31	8
12/31/2025	179	-173	-153	-91	10
12/31/2024	123	-271	-279	-140	10
6/30/2024	102	-261	-169	-128	N/A
3/31/2024	92	-274	-182	-140	N/A
12/31/2023	77	-185	-142	-136	N/A
9/30/2023	62	-186	-146	-141	N/A
6/30/2023	44	-182	-164	-159	N/A
3/31/2023	34	-181	-161	-156	N/A
12/31/2022	24	-181	-174	-173	N/A
9/30/2022	17	-181	-173	-180	N/A
6/30/2022	13	-176	-166	-173	N/A
3/31/2022	5	-166	-160	-166	N/A
12/31/2021	3	-70	-139	-146	N/A
9/30/2021	1	-62	-135	-135	N/A
6/30/2021	0	-60	-122	-122	N/A
3/31/2021	0	-56	-120	-119	N/A
12/31/2020	N/A	-134	-122	-122	N/A
9/30/2020	N/A	-132	-125	-125	N/A
6/30/2020	N/A	-134	-132	-132	N/A
3/31/2020	N/A	-146	-130	-127	N/A
12/31/2019	N/A	-141	-126	-123	N/A
9/30/2019	N/A	-133	-115	-112	N/A
6/30/2019	N/A	-115	-99	-95	N/A
3/31/2019	N/A	-87	-83	-82	N/A
12/31/2018	N/A	-74	-63	-62	N/A
9/30/2018	N/A	-59	-49	-49	N/A
6/30/2018	N/A	-53	-41	-40	N/A
3/31/2018	N/A	-47	N/A	-34	N/A
12/31/2017	N/A	-38	N/A	-29	N/A
9/30/2017	N/A	-36	N/A	-28	N/A
6/30/2017	N/A	-32	N/A	-24	N/A
3/31/2017	N/A	-30	N/A	-24	N/A
12/31/2016	N/A	-29	N/A	-23	N/A
9/30/2016	N/A	-27	N/A	-21	N/A
6/30/2016	N/A	-23	N/A	-18	N/A
3/31/2016	N/A	-17	N/A	-13	N/A
12/31/2015	N/A	-12	N/A	-7	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-3	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-6	N/A
12/31/2014	N/A	-6	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que RYTM sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que RYTM sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que RYTM sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (44% al año) de RYTM crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (44% al año) de RYTM crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: RYTM se prevé que no sea rentable en 3 años.

Rhythm Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Recent updates

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

New minor risk - Profitability

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Executive VP & Head of North America notifies of intention to sell stock

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals: Action Too Specific

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Chief Technical Officer notifies of intention to sell stock

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Forecast to breakeven in 2026

Chief Technical Officer notifies of intention to sell stock

Price target increased by 7.8% to US$47.67

CFO & Treasurer exercised options and sold US$860k worth of stock

Price target increased by 8.4% to US$44.22

CFO & Treasurer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Executive VP & Head of North America exercised options and sold US$180k worth of stock

Executive VP & Head of North America notifies of intention to sell stock

Consensus revenue estimates increase by 28%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 19%

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

Consensus EPS estimates fall by 10%

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Price target increased by 8.6% to US$36.56

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Price target increased to US$33.44

Price target increased to US$33.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind